Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Palomba, M Lia ^a   Piersanti, Kelly ^a   Ziegler, Carly G K ^a   Decker, Hugo ^a   Cotari, Jesse W ^a   Bantilan, Kurt ^a   Rijo, Ivelise ^a   Gardner, Jeff R ^a   Heaney, Mark ^a   Bemis, Debra ^a   Balderas, Robert ^b   Malek, Sami N ^c   Seymour, Erlene ^c   Zelenetz, Andrew D ^a   Van Den Brink, Marcel R M ^a   Altan Bonnet, Grégoire ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BD BIOSCIENCES   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE; PROTEIN KINASE BLNK; PROTEIN KINASE SYK; PROTEIN KINASE X; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; STATISTICAL MODEL;

ANTIBODIES, ANTI-IDIOTYPIC; B-LYMPHOCYTES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEAST-SQUARES ANALYSIS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MODELS, STATISTICAL; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS;

EID: 84900457748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079987     Document Type: Article

References (45)

1. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352: 804-815.
2. Dighiero G, Binet JL (2000) When and how to treat chronic lymphocytic leukemia. N Engl J Med 343: 1799-1801.
3. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, et al. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990-4997. (Pubitemid 26189840)
4. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348: 1764-1775. (Pubitemid 36514707)
5. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, et al. (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98: 181-186.
6. Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, et al. (1996) CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 88: 1365-1374. (Pubitemid 26276812)
7. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847. (Pubitemid 29430399)
8. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916. (Pubitemid 32064784)
9. Ghia P, Chiorazzi N, Stamatopoulos K (2008) Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 264: 549-562.
10. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118: 4313-4320.
11. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P (2010) Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 46: 800-810.
12. Schliep S, Decker T, Schneller F, Wagner H, Hacker G (2004) Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp Hematol 32: 556-562. (Pubitemid 38739467)
13. Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, et al. (2009) The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKC[delta] and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28: 3261-3273.
14. Chiorazzi N, Ferrarini M (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21: 841-894. (Pubitemid 37174549)
15. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, et al. (2009) Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 69: 5424-5432.
16. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, et al. (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115: 369-378. (Pubitemid 40385478)
17. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, et al. (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 100: 3741-3748. (Pubitemid 35303946)
18. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, et al. (2004) A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18: 1391-1400. (Pubitemid 39136749)
19. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, et al. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489: 309-312.
20. JP Sharman JI, G . Coffey, D . Czerwinski, Y . Hitoshi, R . Levy (2007) Targeting Syk kinase for the treatment of B-cell lymphoma. ASCO Meeting Abstracts: 162s.
21. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, et al. (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood.
22. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, et al. (2013) Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology 31: 88-94.
23. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, et al. (2011) Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research 17: 2977-2986.
24. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
25. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, et al. (2013) Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine 369: 32-42.
26. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228. (Pubitemid 38962577)
27. Irish JM, Czerwinski DK, Nolan GP, Levy R (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108: 3135-3142.
28. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, et al. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107: 12747-12754.
29. Palazzo AL, Evensen E, Huang YW, Cesano A, Nolan GP, et al. (2011) Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One 6: e24592.
30. Khalil AM, Cambier JC, Shlomchik MJ (2012) B cell receptor signal transduction in the GC is short-circuited by high phosphatase activity. Science 336: 1178-1181.
31. Lee K, Esselman WJ (2002) Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radic Biol Med 33: 1121-1132.
32. Reth M (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 3: 1129-1134.
33. Behbehani GK, Bendall SC, Clutter MR, Fantl WJ, Nolan GP (2012) Single-cell mass cytometry adapted to measurements of the cell cycle. Cytometry A 81: 552-566.
34. Mukherjee S, Zhu J, Zikherman J, Parameswaran R, Kadlecek TA, et al. (2013) Monovalent and Multivalent Ligation of the B Cell Receptor Exhibit Differential Dependence upon Syk and Src Family Kinases. Sci Signal 6: ra1.
35. Cotari JW, Voisinne G, Altan-Bonnet G (2013) Diversity training for signal transduction: leveraging cell-to-cell variability to dissect cellular signaling, differentiation and death. Curr Opin Biotechnol 24: 760-766.
36. Cotari JW, Voisinne G, Dar OE, Karabacak V, Altan-Bonnet G (2013) Cell-to-cell variability analysis dissects the plasticity of signaling of common gamma chain cytokines in T cells. Sci Signal 6: ra17.
37. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638. (Pubitemid 33126813)
38. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647. (Pubitemid 33126814)
39. Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, et al. (2004) Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 113: 1008-1016. (Pubitemid 38544122)
40. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 109: 259-270. (Pubitemid 46070124)
41. Widhopf GF, 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, et al. (2004) Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 104: 2499-2504. (Pubitemid 39331853)
42. Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, et al. (2012) Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma. BMC Cancer 12: 478.
43. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, et al. (2012) Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120: 1274-1281.
44. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Lovendorf MB, Ahler CB, et al. (2011) Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 118: 5891-5900.
45. Song Z, Lu P, Furman RR, Leonard JP, Martin P, et al. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 16: 587-599.